Dec 22, 2022 | Gail McCray
Overall: As with every ASH, we are able to witness up close and personal the exciting advances in science and medicine – the research moving us more and more towards precision medicine, the current clinical trials (phases I, II, and III) and the medications approved...
Dec 19, 2022 | Michael Tuohy
Targets in myeloma are interesting and hopeful for our futures as bispecific antibodies continue to become a key treatment option. Using the immune system to fight multiple myeloma makes great sense to me. It’s exciting to follow trials targeting BCMA as part of the...
Dec 12, 2022 | John DeFlice
“The impossible exists only until we find a way to make it possible.” Mike Horn Emily Whitehead was five years old when she was diagnosed with acute lymphoblastic leukemia (ALL). After being treated with chemotherapy for two years, she experienced a failure of therapy...
Dec 12, 2022 | Becky Bosley
Saturday at ASH was INTENSE! Virtually taking in content from 7 a.m. until 9:30 p.m. While I’m exhausted, I’m energized at the same time. So much amazing research being done for the good of the patient with myeloma. I think the thing that struck me the most today was...
Dec 11, 2022 | Linda Huguelet
On Saturday, our team had the distinct privilege to attend the International Myeloma Working Group (IMWG) meeting. This organization includes over 280 myeloma specialists and researchers from all over the world who share the same goal of advancing myeloma research...
